Key Points
- Cosmos Health CEO Grigorios Siokas bought 291,262 shares on Feb. 11 at an average price of $0.41, a total purchase of $119,417.42, bringing his ownership to 8,473,382 shares (a ~3.56% increase).
- The Feb. 11 trade is part of an ongoing string of insider purchases by Siokas since November, totaling hundreds of thousands of shares and signaling concentrated insider accumulation.
- Cosmos Health is a micro‑cap (~$13.97M) with negative earnings and margins, and carries a consensus Sell stance, including a Weiss Ratings “sell (d-)” rating.
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 291,262 shares of Cosmos Health stock in a transaction dated Wednesday, February 11th. The stock was purchased at an average cost of $0.41 per share, with a total value of $119,417.42. Following the completion of the purchase, the chief executive officer owned 8,473,382 shares of the company's stock, valued at approximately $3,474,086.62. This represents a 3.56% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Grigorios Siokas also recently made the following trade(s):
- On Friday, January 23rd, Grigorios Siokas bought 90,325 shares of Cosmos Health stock. The shares were purchased at an average price of $0.50 per share, for a total transaction of $45,162.50.
- On Tuesday, January 20th, Grigorios Siokas bought 353,321 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.50 per share, with a total value of $176,660.50.
- On Wednesday, January 14th, Grigorios Siokas purchased 493,495 shares of Cosmos Health stock. The stock was acquired at an average price of $0.45 per share, with a total value of $222,072.75.
- On Monday, January 12th, Grigorios Siokas acquired 113,185 shares of Cosmos Health stock. The stock was acquired at an average price of $0.50 per share, for a total transaction of $56,592.50.
- On Thursday, January 8th, Grigorios Siokas acquired 156,190 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.52 per share, with a total value of $81,218.80.
- On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The shares were acquired at an average price of $0.52 per share, with a total value of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas bought 133,953 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.54 per share, for a total transaction of $72,334.62.
- On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The stock was acquired at an average price of $0.49 per share, with a total value of $43,273.86.
- On Monday, December 15th, Grigorios Siokas acquired 168,472 shares of Cosmos Health stock. The shares were bought at an average price of $0.42 per share, for a total transaction of $70,758.24.
- On Friday, November 28th, Grigorios Siokas bought 76,360 shares of Cosmos Health stock. The stock was bought at an average cost of $0.64 per share, for a total transaction of $48,870.40.
Cosmos Health Price Performance
Shares of NASDAQ:COSM opened at $0.37 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.84 and a current ratio of 0.99. The firm has a fifty day moving average price of $0.49 and a 200 day moving average price of $0.73. Cosmos Health Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $1.32. The firm has a market cap of $13.97 million, a price-to-earnings ratio of -0.50 and a beta of 5.36.
Cosmos Health (NASDAQ:COSM - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.16). The company had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. As a group, sell-side analysts expect that Cosmos Health Inc. will post -0.78 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cosmos Health in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cosmos Health has an average rating of "Sell".
Check Out Our Latest Report on COSM
Hedge Funds Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC grew its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 225,507 shares of the company's stock after buying an additional 128,776 shares during the quarter. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 at the end of the most recent reporting period. 12.61% of the stock is currently owned by institutional investors.
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
